Author Review — inspect what researchers actually reported
Aggregate an author's papers' raw data, methods, conflicts, and reproducibility cues.
Press Enter ↵ to lookup
Explore by Goal
"The most incomprehensible thing about the world is that it is comprehensible."
- Albert Einstein
Quick Explanation
Copied
Sang Kun Lee (as identified in the provided OpenAlex record)
Based only on the specific paper excerpts you provided, Lee’s visible scientific footprint strongly clusters around CNS/neuroimmunology and human translational biomarkers, with methodological strengths in (i) evidence-synthesizing clinical guidance and (ii) blinded imaging biomarker scoring with predictive modeling in a retrospective cohort.
Epistemic stance: skeptical and evidence-bound. This review uses only the content you provided in the prompt (not assumptions about the rest of the author’s career). Therefore, scope is limited.
Visual evidence snapshot (from provided datasets)
Two provided works are used as the evidentiary base for the quantitative plots below.
Primary source for these regression outputs:
AUC values plotted above are from the provided risk-score performance results: .
Follow-up MRI counts come from the provided extraction for the cryptococcal cohort:
What the author’s provided outputs suggest (known vs inferred)
1) Translational synthesis in CNS autoimmunity (review paper)
The provided review discusses autoimmune encephalitis treatment strategies and emphasizes early aggressive immunotherapy, the role of first-line agents (e.g., corticosteroids, IVIg, plasma exchange), and second-line escalation (e.g., rituximab/cyclophosphamide), while also noting a lack of randomized controlled trials and the heterogeneity across neuronal autoantibodies.
Science strength signal: the review’s value proposition is practical evidence synthesis under uncertainty, while explicitly highlighting where evidence quality is limited (no RCTs) and where observational heterogeneity is expected.
Critical caveat: because this is a review, scientific rigor depends on (i) how the review authors assessed evidence quality and bias, (ii) whether they used systematic methods (not provided in the excerpt), and (iii) whether treatment-effect claims are limited to what observational data can justify. The prompt excerpt indicates these constraints, but does not provide a full PRISMA-like methodology.
2) Human biomarker prognostication with imaging scoring (retrospective cohort)
In the cryptococcal meningoencephalitis cohort, the provided excerpt reports that baseline MRI features—specifically enlarged periventricular space (ePVS), periventricular lesion extension, cryptococcoma, and hydrocephalus—are associated with 6-month neurological outcomes and mortality, and that the analysis includes a blinded imaging scoring procedure and inter-reader reliability metrics.
Science strength signal: the combination of (i) blinded scoring, (ii) multivariate modeling for predictors of poor outcome, and (iii) a parsimonious risk score with reported discriminative performance (AUCs) supports the plausibility of the biomarker approach—while still being vulnerable to retrospective confounding and overfitting concerns typical of single-center designs.
Critical caveat (effect size inflation risk): the dichotomized ePVS ≥5 OR reported in the excerpt comes with an extremely wide confidence interval (very large upper bound), which is consistent with sparse events / limited sample sizes in some strata or collinearity. This does not invalidate the association, but it reduces precision and raises the need for external validation in independent cohorts.
Scientific citation-metric signals (what we can and cannot conclude)
The prompt includes OpenAlex-like bibliometrics for identically named authors (e.g., “Sang Kun Lee”), but no DOIs/traceable evidence were provided for those metrics as a citable source.
Because you require inline DOI-form citations for claims, I am not asserting additional numerical bibliometrics here.
If you provide a specific DOI list (or a citable bibliometrics source page), I can compute citation/impact summaries with proper traceability.
Blind spots & what would change my confidence
Scope limitation: this review is only as strong as the two provided works’ excerpts; many aspects of an author’s overall rigor (experimental design variety, reproducibility practices, data transparency, preregistration, etc.) are not assessable from the prompt alone.
Retrospective confounding: the cryptococcal cohort is retrospective and single-center over a long period, with heterogeneous imaging strength and non-standardized treatment regimens noted in the excerpt; these can bias predictor-outcome associations.
External validity: prognostic biomarkers often fail when ported to new scanners, populations, or outcome definitions; the excerpt itself emphasizes potential misclassification (ePVS vs small vessel disease aging effects) and limited generalizability.
Review bias risk: for the autoimmune encephalitis treatment review, observational evidence may be subject to selection bias and publication bias; without the full review methodology, the robustness of evidence grading can’t be fully audited from the excerpt alone.
Overall assessment (confidence-bounded)
Known from provided evidence: the excerpts show involvement in (a) clinically oriented CNS autoimmune treatment synthesis with explicit evidence limitations, and (b) a blinded imaging biomarker prognostic study with reported inter-reader reliability and predictive discrimination metrics.
Uncertainty: without additional independent datasets/publications, I cannot determine whether these are isolated strengths or part of a broader consistently rigorous research program.
BGPT quick links (bespoke)
Feedback:
Updated: March 29, 2026
BGPT Author Review
Scientific Quality
60%
Based on the provided excerpts only, the work shows credible scientific skills: blinded biomarker scoring with inter-reader reliability and predictive modeling (moderate strength), and clinical synthesis that explicitly flags the absence of RCTs and observational bias risk (moderate strength). However, the evidence does not include enough detail to assess reproducibility, data transparency, preregistration, robustness checks, or broader experimental contributions across the author’s full publication record.
Communication Quality
60%
The extracted summaries read as structured and clinically/biostatistically oriented, with clear statements of limitations and reported effect sizes/AUCs. But the prompt does not include the full prose of the author’s writing, so communication quality cannot be fully audited beyond the excerpted content.
Author Novelty
50%
The biomarker study’s novelty appears to be the specific baseline MRI scoring approach/risk score for cryptococcal meningoencephalitis, and the review’s novelty is less about methods and more about consolidating practice; overall novelty can’t be judged broadly without a fuller corpus.
Scientific Rigor
60%
Rigor signals include blinded image analysis and reported inter-reader reliability plus multivariate modeling; limitations appropriate to retrospective design are acknowledged. Still, the wide CIs and retrospective/single-center constraints suggest moderate rather than high rigor in predictive certainty, and review-method rigor isn’t fully auditable from the excerpt.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The risk score discriminates purely because it is a surrogate for unmeasured baseline severity rather than ePVS physiology; it is less plausible if future external cohorts show maintained calibration after adjustment for severity markers.
The review’s “early aggressive immunotherapy improves outcomes” claim is not just confounded but structurally wrong because observational cohorts are too biased; this would be less likely if multiple independent, well-adjusted cohorts show consistent directionality.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Hypothesis Graveyard
Discussion